Carnot CALYM

The Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field

The CALYM Carnot Institute fosters together 20 research teams specialized in lymphoma, first blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offer spanning from the identification of new biological targets to registration clinical trials.


A Carnot Institute Devoted to Lymphoma: creating synergies, initiating partnerships, accelerating translational research

Target markets

  • Pharmaceutic industry
  • Biotechnologies
  • In vitro diagnosis
  • Imaging
  • Artificial Intelligence

Our 4 R&D Pillars at the Core of Innovation

  1. Research and validation of new biological targets and lymphoma in vitro and in vivo models
    > to develop new preclinical drug candidates
  2. Identification, validation, patenting and licensing of blood and tissue biomarkers
    > to improve diagnosis, guide therapy decisions and predict tumor responses
  3. Early monitoring of activity (early pharmacodynamic markers, circulating DNA, immunomonitoring)
    > to accelerate translational research
4. Optimization and exploitation of clinical research related tools
> to accelerate development, registration and market access of drug candidates


Consortium overview 

20 multidisciplinary and complementary research entities in the lymphoma field:
  • LYSA: The Lymphoma Study Association, a cooperative group
  • LYSARC: The Lymphoma Academic Research Organisation
  • 18 academic research teams (belonging to Inserm or CNRS national research bodies, to universities and/or to hospitals)


CALYM is certified ISO 9001:2015
for the management and monitoring of its research activities
and for its coordination of viable cell collection - CeVi



CALYM is member of FINDMED